Can probenecid or febuxostat be co‑prescribed with azathioprine?

Azathioprine and Xanthine Oxidase Inhibitors: Contraindicated Combination

Neither probenecid nor febuxostat should be co-prescribed with azathioprine without critical dose adjustments, and febuxostat specifically carries a contraindication for this combination. 1, 2

Critical Drug Interaction with Febuxostat

Febuxostat is contraindicated with azathioprine due to risk of severe, life-threatening myelotoxicity. 3, 4, 1

• The FDA drug label for azathioprine explicitly states: "Concomitant use of AZASAN with febuxostat is not recommended" due to inhibition of xanthine oxidase pathways leading to accumulation of toxic azathioprine metabolites. 1

• The British Association of Dermatologists guidelines warn of "severe, life-threatening myelotoxicity" when azathioprine is combined with xanthine oxidase inhibitors including febuxostat. 3, 4

• A 2020 case series from the FDA Adverse Event Reporting System documented 19 cases of myelosuppressive events with febuxostat-azathioprine combination, with 16 requiring hospitalization and 15 requiring blood product administration, occurring within a median of 1.6 months. 2

Mechanism of Toxicity

• Febuxostat inhibits xanthine oxidase, one of the primary inactivation pathways for azathioprine, causing increased plasma concentrations of azathioprine's active metabolite 6-mercaptopurine (6-MP), leading to severe bone marrow suppression. 1, 5

• This interaction is particularly dangerous because it blocks a major detoxification route, resulting in accumulation of toxic metabolites. 2

Probenecid with Azathioprine: No Direct Interaction

Probenecid can be safely co-prescribed with azathioprine as there is no documented direct pharmacologic interaction between these agents. 3, 4, 6

• The British Association of Dermatologists guidelines do not list probenecid among drugs that interact with azathioprine. 3, 4

• The FDA drug label for probenecid does not mention azathioprine as an interacting medication. 6

• Probenecid works by blocking renal tubular reabsorption of uric acid and does not affect xanthine oxidase or thiopurine methyltransferase (TPMT) pathways that metabolize azathioprine. 6

Monitoring Considerations

• Standard complete blood count monitoring for azathioprine should continue (weekly during first month, twice monthly for months 2-3, then monthly), with no additional monitoring specifically required for probenecid co-administration. 4, 1

• Probenecid may not be effective in chronic renal insufficiency when glomerular filtration rate is ≤30 mL/minute, which is a separate clinical consideration. 6

Clinical Algorithm for Decision-Making

If a patient on azathioprine requires urate-lowering therapy:

1. Avoid febuxostat entirely - this is a contraindicated combination. 1, 2

2. Probenecid is safe to use with standard azathioprine monitoring protocols. 3, 4, 6

3. If allopurinol is considered (not asked but relevant), azathioprine dose must be reduced to approximately 25-33% of the usual dose due to similar xanthine oxidase inhibition. 1

Common Pitfalls to Avoid

• Do not assume all urate-lowering therapies have the same interaction profile - febuxostat and allopurinol both inhibit xanthine oxidase and interact dangerously with azathioprine, while probenecid works through a completely different mechanism (uricosuric) and does not interact. 3, 1, 6

• Do not attempt dose adjustment strategies with febuxostat-azathioprine - unlike allopurinol where dose reduction protocols exist, febuxostat combination is not recommended at any dose. 1

• Monitor for early signs of myelosuppression if any xanthine oxidase inhibitor must be used - most adverse events occur within the first 2 months of combination therapy. 2